March 11, 2022 – Medigen, Inc’s Dr. Irina Tretyakova and Dr. Peter Pushko in collaboration with Dr. John Vasilakos (Kindeva) and Dr. Tomai (3M) have published the manuscript titled Live-Attenuated VEEV Vaccine Delivered by iDNA using Microneedles is Immunogenic in Rabbits in Frontiers in Tropical Diseases, 2 Mar 2022.
The authors demonstrate induction of neutralizing antibody in rabbits vaccinated with a novel naked DNA vaccine that encodes live-attenuated Venezuelan equine encephalitis virus (VEEV). High titers of neutralizing antibodies to VEEV were detected following a single intradermal administration of Medigen’s VEEV vaccine with Kindeva’s hollow microneedle device.
The findings highlight the vaccine potential of naked DNA administered intradermally without the need for electroporation. Thus, combination of iDNA vaccine and hollow microneedle device improves vaccination with live-attenuated vaccines by providing simple, single-dose immunization.
About Kindeva Drug Delivery
Kindeva is a global contract development manufacturing organization focused on drug-device combination products. Kindeva develops and manufactures products across a broad range of complex drug-delivery formats, including autoinjectors, inhalers, transdermal patches, and microneedles. Its service offering spans early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva serves a global client base in the commercial and health security markets from its nine manufacturing and research and development facilities located in the U.S. and U.K. For more information, please visit kindevastg.wpenginepowered.com.
About Medigen, Inc.
Medigen is an independent prophylactic and therapeutic vaccine company founded in 2004. The company is headquartered in Frederick, Maryland. Medigen develops vaccines against emerging infectious diseases. Medigen vaccines are based on unique, proprietary technologies designed to elicit safe, natural immune responses for efficient, long-term immunity. Proprietary vaccine technologies include VLPs, RNA vectors, iDNA, and reassortant virus. www.medigen-usa.com
Related news
Explore more of our latest news and announcements, where the demands of today meet the possibilities of tomorrow.
Kindeva Drug Delivery awarded up to $129 million to supply DuoDote® autoinjectors to the Strategic National Stockpile
ST. LOUIS, Mo. and WOODBURY, Minn: 16th Jan 2025 (Business Wire) – Kindeva Drug Delivery’s global health security division, Meridian Medical Technologies, LLC, secured a contract valued at up to $129 million to supply DuoDote®, a chemical nerve agent antidote autoinjector, to the Strategic National Stockpile (SNS), managed by the Administration for Strategic Preparedness and […]
Learn More Kindeva Drug Delivery and Emervax partner to bring game changing vaccine administration to patients
Woodbury, Minnesota and Houston, Texas – JAN 09, 2025: Kindeva Drug Delivery, a global CDMO and drug delivery expert, and Emervax, a developer of a proprietary circular RNA-based vaccine platform (emxRNATM), today announced an exclusive partnership to co-develop a game-changing solution for the administration of vaccines targeting a variety of emerging viruses. Kindeva has granted […]
Learn More Kindeva Global Health Security donates ATNAA to Ukraine through the European Commission’s rescEU and Governmental Strategic Reserves Agency (RARS)
WOODBURY, Minn. and ST. LOUIS, Mo.; May 29, 2024 (Business Wire) – Kindeva Drug Delivery (Kindeva), a leading global health security provider of CBRN medical countermeasures, announced that it donated a supply of autoinjectors — specifically an antidotal treatment for chemical nerve agents — to Ukraine through the rescEU reserve of the EU Civil Protection […]
Learn More Kindeva Drug Delivery and Syntegon install first Versynta microBatch in North America
Waiblingen, Germany/Minneapolis, USA, April 9, 2024. Syntegon today announced the sale of its newly developed Versynta microBatch production cell to its first U.S. customer. Kindeva Drug Delivery will use Versynta microBatch to further expand its suite of aseptic fill-finish contract development and manufacturing (CDMO) capabilities meeting the latest global pharmaceutical regulations and trends. Kindeva is […]
Learn More Kindeva Drug Delivery acquires Summit Biosciences, a specialized Nasal Drug Development and Manufacturing organization
WOODBURY, Minn., ST. LOUIS, Mo., LEXINGTON, Ky.; Jan. 18, 2024 (Business Wire) Kindeva Drug Delivery (“Kindeva”), a global leader in drug-device combination products, announced today that it has acquired Summit Biosciences Inc. (“Summit”), an intranasal drug-delivery contract development and manufacturing organization (CDMO), from its founding family shareholders. Established in 2009, Summit has an extensive track […]
Learn More Nutriband signs Commercial Development and Clinical Supply Agreement with Kindeva Drug Delivery for Aversa™ Fentanyl, an abuse deterrent fentanyl patch
ORLANDO, FL / ACCESSWIRE / January 5, 2024 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a company engaged in the development of transdermal pharmaceutical products, today announced it has signed a commercial development and clinical supply agreement for their lead product, Aversa™ Fentanyl, with their partner, Kindeva Drug Delivery, a leading global contract development and manufacturing organization (CDMO) […]
Learn More Kindeva Drug Delivery and Orbia Fluorinated Solutions (Koura) announce collaboration for Low GWP Propellant Conversion
WOODBURY, Minn. and St. LOUIS, Mo. and BOSTON; Dec. 5, 2023 – Kindeva Drug Delivery (Kindeva), a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, and Orbia Advance Corporation, S.A.B. de C.V. (BMV: ORBIA*) Fluorinated Solutions business (Koura®), a global leader in the development, manufacture, and supply of fluoroproducts and […]
Learn More Meridian Medical Technologies, Kindeva Drug Delivery’s Global Health Security Division, awarded contract to supply DuoDote®
ST. LOUIS, Mo. and WOODBURY, Minn.; Nov. 14, 2023 (Business Wire) – Meridian Medical Technologies, LLC (Meridian), a division of Kindeva Drug Delivery (Kindeva), has been awarded a $9.9M contract to supply DuoDote® to the Administration for Strategic Preparedness and Response (ASPR) within the United States (U.S.) Department of Health and Human Services. Meridian is […]
Learn More Meridian Medical Technologies, LLC, and the European Commission’s DG HERA sign agreement for 13 countries from the EEA to purchase Tecovirimat SIGA
ST. LOUIS, Mo. and WOODBURY, Minn.; Oct. 23, 2023 (Business Wire) – Meridian Medical Technologies, LLC (Meridian), a global health security leader in providing medical countermeasures, today announced a framework contract under the Joint Procurement Agreement (JPA) was signed between Meridian and the European Commission’s Directorates-General (DG) HERA (Health Emergency Preparedness and Response Authority). As […]
Learn MoreManufacturing more tomorrows
Partner with us and benefit from a team with technical expertise and a passion for purpose. As a true partner, strategically minded and dedicated to your lasting legacy, we provide customized solutions tailored to your precise requirements. From development to commercial manufacturing and beyond, our CDMO solutions are designed to help your product progress with purpose.
